

03-16-04 05:09pm From-PILLBURY WINTHROP CARMEL VLY

+858-509-4010

T-549 P.004/027 F-177

FORM PTO-1449 (modified)
 To: U.S. Department of Commerce
 (PW FORM PAT-1449)
 Patent and Trademark Office

Atty. Dkt. No.	MM	Client Ref.
027579	0302598	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date: March 16, 2004

Page 1 of 1

Applicant: Gold, et al.

Appln. No.: 09/927,121

Filing Date: August 10, 2001

Examiner: Jessica H. Roark Group Art Unit: 1644

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
JHR	A. 6,063,905	05/16/2000	Capra et al.			
	B.					
	C.					
	D.					
	E.					
	F.					
	G.					
	H.					

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
I.						
J.						
K.						
L.						
M.						
N.						

OTHER (Including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

O.						
P.						
Q.						
R.						
S.						
T.						
U.						
V.						
W.						
X.						
Y.						
Z.						

Examiner <i>JHR</i>	Date Considered: 3/25/07
---------------------	--------------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)
 To: U.S. Department of Commerce
 (PW FORM PAT-1449)
 Patent and Trademark Office

Atty. Dkt. No.	M#	Client Ref.
027579	0302598	

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date: March 11, 2004

Page **1** of **9**

Applicant: Gold, et al.

Appln. No.: 09/927,121

Filing Date: August 10, 2001

Examiner: Jessica H. Roark | Group Art Unit: 1644

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
JHL	A. 4,338,397	07/06/1982	Gilbert et al.			
	B. 4,399,216	08/16/1983	Axel et al.			
	C. 4,444,878	04/24/1984	Paulus			
	D. 4,468,464	08/28/1984	Cohen et al.			
	E. 4,512,922	04/23/1985	Jones et al.			
	F. 4,634,665	01/06/1987	Axel et al.			
	G. 4,704,362	11/03/1987	Itakura et al.			
	H. 4,840,896	06/20/1989	Reddy et al.			
	I. 5,078,996	01/07/1992	Conlon III, et al.			
	J. 5,162,111	11/10/1992	Grabstein et al.			
	K. 5,179,017	01/12/1993	Axel et al.			
	L. 5,229,496	07/20/1993	Deeley et al.			
	M. 5,254,534	10/19/1993	Tachibana et al.			
	N. 5,334,379	08/02/1994	Pillai et al.			
	O. 5,478,556	12/26/1995	Elliott et al.			
	P. 5,580,561	12/3/1996	Cercek et al.			
	Q. 5,602,007	02/11/1997	Dunn et al.			
	R. 5,679,347	10/21/1997	Porcelli et al.			
	S. 5,728,377	03/17/1998	Sarris et al.			
	T. 5,891,429	04/06/1999	Clark et al.			
	U. 5,891,432	04/06/1999	Hoo			
	V. 5,895,646	04/20/1999	Wang			
	W. 5,900,238	05/04/1999	Gombotz et al.			
	X. 5,904,920	05/18/1999	Dranoff et al.			
	Y. 5,929,196	07/27/1999	Kissel et al.			
	Z. 5,942,221	08/24/1999	Clark et al.			
	AA. 5,942,253	08/24/1999	Gombotz et al.			
	BB. 5,980,911	11/09/1999	Corner et al.			
	CC. 6,080,409	06/27/2000	Laus et al.			
JKL	DD. 6,083,521	07/04/2000	Acemoglu et al.			

Examiner *J. Roark* Date Considered: *3/29/04*

AMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified) To: U.S. Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office				Atty. Dkt. No.	M#	Client Ref.
				027579	0302598	
				Applicant: Gold, et al.		
				Appln. No.: 09/927,121		
				Filing Date: August 10, 2001		
Date: March 11, 2004				Page 2 of 9	Examiner: Jessica H. Roark	Group Art Unit: 1644

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
DR	EE. 6,083,703	07/04/2000	Wang et al.			
	FF. 6,087,110	07/11/2000	Wang et al.			
	GG. 6,096,313	08/01/2000	Jäger et al.			
	HH. 6,120,807	09/19/2000	Gombotz et al.			
	II. 6,274,175 B1	08/14/2001	Gombotz et al.			
	JJ. 6,309,632 B1	10/30/2001	Agosti			
	KK. 6,312,718 B1	11/06/2001	Popescu et al.			
	LL. 6,331,415 B1	12/18/2001	Cabilly et al.			
	MM. 6,338,953 B1	01/15/2002	Boyce et al.			
	NN. 6,338,962	01/15/2002	Boyce			
	OO. 6,342,216 B1	01/29/2002	Fidler et al.			
	PP. 6,348,449 B1	02/19/2002	Weiner et al.			
DR	QQ. 6,361,948 B1	03/26/2002	Tricoli et al.			

FOREIGN PATENT DOCUMENTS					English Abstract	Translation Readily Available
	Document Number	Date MM/YYYY	Country	Inventor Name		
DR	RR. 2,139,756	01/20/1994	CA	Bonnem et al.		
	SS. 0183350 B1	01/15/1992	EP	Anderson et al.		
	TT. 0326149 B1	08/18/1993	EP	Tachibana et al.		
	UU. 0370656 A1	05/30/1990	EP	Bonnem		
	VV. 0382381 B1	05/26/1993	EP	Bonnem		
	WW. 2658432 A1	08/23/1991	FR	Henri		
	XX. 1-193227	08/03/1989	JP	Tachibana et al.	(Abstract Only)	X
	YY. 6289621 62087621	04/24/1987	JP	Conlon et al.	(Abstract Only)	X
	ZZ. 62230729	09/10/1987	JP	Takaharu et al.	(Abstract Only)	X
	AAA. 02-002390	01/08/1990	JP	Matsuki et al.	(Abstract Only)	X
	BBB. 64-027492	01/30/1989	JP	Boone	(Abstract Only)	X
	CCC. 02-076820	03/16/1990	JP	Kishimoto et al.	(Abstract Only)	X
DR	DDD. 2000-256209	09/19/2000	JP	Shimamura et al.	(Abstract Only)	X

Examiner *JR* Date Considered: 3/29/04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified) To: U.S. Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office			Atty. Dkt. No.	M#	Client Ref.
			027579	0302598	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
Date: March 11, 2004			Page 3 of 9	Applicant: Gold, et al.	
				Appln. No.: 09/927,121	
				Filing Date: August 10, 2001	
				Examiner: Jessica H. Roark	Group Art Unit: 1644

FOREIGN PATENT DOCUMENTS						English Abstract	Translation Readily Available
	Document Number	Date MM/YYYY	Country	Inventor Name			
DNL	EEE 88/00832	02/11/1988	WO	Grabstein		X	
	FFF 91/05046	04/18/1991	WO	Smith			
	GGG 93/20835	10/28/1993	WO	Bonnem et al.			
	HHH 94/01133	01/20/1994	WO	Bonnem et al.	(Abstract Only)	X	
	III. 96/10395	04/11/1996	WO	Cox	(Abstract Only)	X	
	JJJ. 97/13502	04/17/1997	WO	Gombotz et al.			
DNL	KKK 98/16246	04/23/1998	WO	Brem et al.			

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)			
DNL	LLL ACCOLLA, et al., "Monoclonal antibodies specific for carcinoembryonic antigen and produced by two hybrid cell lines," <i>Proc. Natl. Acad. Sci. USA.</i> , 77(1):563-566 (1980)		
	MMM ADAMS, et al., "Molecular Cloning of Mouse Immunoglobulin Heavy Chain Messenger Ribonucleic Acids Coding for, μ , α , γ_1 , γ_2a , and γ_3 Chains," <i>Biochemistry</i> , 19:2711-2719 (1980)		
	NNN ADVANI, et al., "Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as an Adjunct to Autologous Hemopoietic Stem Cell Transplantation for Lymphoma," <i>Annals of Internal Medicine</i> , 116(3):183-189 (1992).		
	OOO AMSTER, "Synthesis of part of a mouse immunoglobulin light chain in a bacterial clone," <i>Nucleic Acids Research</i> , 8(9):2055-2065 (1980)		
	PPP AZUMA, et al., "Stimulation of Host-Defense Mechanism with Synthetic Adjuvants and Recombinant Cytokines Against Viral Infection in Mice," in Friedman, et al., ed., <i>Microbial Infections</i> , Plenum Press, New York, pp. 253-263 (1992).		
	QQQ BACKMAN and PTASHNE, "Maximizing Gene Expression on a Plasmid Using Recombination in Vitro," <i>Cell</i> , 13:65-71 (1978)		
	RRR BALTIMORE, et al., "Expression of the Abelson Murine Leukemia Virus Genome and of Transfected κ Immunoglobulin Genes," <i>Journal of Cellular Biochemistry</i> , 12 th Annual UCLA Symposia Abstracts, Suppl. 7A, Abstract 0224 (1983)		
	SSS BANERJI, et al., "Expression of a β -Globin Gene Is Enhanced by Remote SV40 DNA Sequences," <i>Cell</i> , 27:299-308 (1981)		
	TTT BENDANDI, "Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma," <i>Expert Rev. Anticancer Ther.</i> , 1(1):65-72 (2001)		
	UUU BERNARD, et al., "Sequences of Mouse Immunoglobulin Light Chain Genes before and after Somatic Changes," <i>Cell</i> 15:1133-1144 (1978)		
	VVV BIXLER and PILLAI, "Augmentation by Interleukins of the Antibody Response to a Conjugate Vaccine Against <i>Haemophilus Influenza B</i> ," in Atassi, ed., <i>Immunobiology of Proteins and Peptides VI</i> , Plenum Press, New York, pp. 185-190 (1991)		
DNL	WWW BONNEM, "Alpha Interferon: The Potential Drug of Adjuvant Therapy: Past Achievements and Future Challenges, <i>Eur. J. Cancer</i> , 27(Suppl. 4):S2-S7 (1991)		

Examiner <i>J. Roark</i>	Date Considered: <i>3/21/04</i>
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 (modified) To: U.S. Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office		Atty. Dkt. No.	M#	Client Ref.
			027579	0302598
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Gold, et al.		
		Appln. No.: 09/927,121		
		Filing Date: August 10, 2001		
Date: March 11, 2004		Page 4 of 9	Examiner: Jessica H. Roark Group Art Unit: 1644	
FOREIGN PATENT DOCUMENTS				English Abstract Translation Readily Available
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)				
212	XXX	BONNEM, "Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): Biology and Potential Clinical Utility," in Oldham, ed., <u>Principles of Cancer Biotherapy</u> , 2 nd ed., Marcel Dekker, Inc., New York, Chapter 20, pp. 585-598 (1991)		
	YYY	BONNEM, "Granulocyte-macrophage colony stimulating factor – issues in patient management," in Maroun, et al., eds., <u>Colony-Stimulating Factors in Clinical Practice</u> , International Congress and Symposium Series Number 184, Royal Society of Medicine Services Limited, London, pp. 17-22 (1992)		
	ZZZ	BONNEM, "Granulocyte-Macrophage Colony-Stimulating Factor: Unrealized Potential," in Murphy, ed., <u>Blood Cell Growth Factors: Their Present and Future Use in Hematology and Oncology</u> , AlphaMed Press, Dayton, Ohio, pp. 3-20 (1991)		
	AAA	BONNEM and MORSTYN, "Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Current Status and Future Development," <u>Seminars in Oncology</u> , 15(5)(Suppl. 5):46-51 (1988)		
	BBB	BONNEM, et al., "Summary of Preclinical/Clinical Phase I Studies with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)," <u>Investigational New Drugs: The Journal of New Anticancer Agents</u> , Abstract 235, 7(4):407 (1989)		
	CCC	BOSS and EMTAGE, "Expression of an Immunoglobulin Light Chain Gene in Escherichia Coli," <u>Gene Expression</u> , Alan R. Liss, Inc., New York, pp. 513-522 (1983)		
	DDD	CLARK and CROCE, "An Autonomously Replicating Vector for Mammalian Cells," <u>Plasmids and Transforming Vectors</u> , Fed Proc. 1983, Abstract 2364		
	EEE	COLMAN, et al., "Interactions of Mouse Immunoglobulin Chains within <u>Xenopus Oocytes</u> ," <u>J. Mol. Biol.</u> , 160:459-474 (1982)		
	FFFF	DOLBY, et al., "Cloning and partial nucleotide sequence of human immunoglobulin μ chain cDNA from B cells and mouse-human hybridomas," <u>Proc. Natl. Acad. of Sci. USA</u> , 77(10):6027-6031 (1980)		
	GGG	DUMANN, et al., "Influence of Thymopentin on Antibody Response, and Monocyte and T Cell Function in Hemodialysis Patients Who Fail to Respond to Hepatitis B Vaccination," <u>Nephron</u> , 55:136-140 (1990)		
	HHH	FALKNER and ZACHAU, "Expression of mouse immunoglobulin genes in monkey cells," <u>Nature</u> , 298:286-288 (1982)		
	IIII.	FRIEDMANN, et al., "Introduction Of The Human HPRT Gene Into Mammalian Cells By An Infectious Retroviral Vector," <u>Control of Phospholipid Metabolism</u> , Fed Proc. 1983, Abstract 1736		
	JJJJ	FUJISAWA, et al., "Direct expression of hepatitis B surface antigen gene in E. coli," <u>Nucleic Acids Research</u> , 11(11):3581-3591 (1983)		
(abstrat o-3) 212	KKK	FULIANO, et al., "La timopentina come terapia adiuvante nella vaccinazione anti-epatite B in soggetti non-O iporesponsivi," <u>Minerva Medica</u> , 81(5): 407-413 (1990)		
Examiner <i>Jessica Roark</i>		Date Considered: 3/25/01		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.				

FORM PTO-1449 (modified) To: U.S. Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office		Atty. Dkt. No.	M#	Client Ref.
			027579	0302598
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Gold, et al.		
		Appln. No.: 09/927,121		
		Filing Date: August 10, 2001		
Date: March 11, 2004		Page 5 of 9	Examiner: Jessica H. Roark	Group Art Unit: 1644
FOREIGN PATENT DOCUMENTS				English Abstract Translation Readily Available
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)				
APR	LLL	GILLIES, et al., "A Tissue-specific Transcription Enhancer Element is Located in the Major Intron of a Rearranged Immunoglobulin Heavy Chain Gene," <u>Cell</u> , 33:717-728 (1983)		
	MM	GILLIES and TONEGAWA, "Expression of cloned immunoglobulin genes introduced into mouse L cells," <u>Nucleic Acids Research</u> , 11(22):7981-7997 (1983)		
	NNN	GLENNIE and STEVENSON, "Univalent antibodies kill tumour cells <u>in vitro</u> and <u>in vivo</u> ," <u>Nature</u> , 295:712-714 (1982)		
	OOC	GOUGH, "The rearrangements of immunoglobulin genes," in Tooze, et al., eds., <u>Trends in Biochemical Sciences</u> , Reference Edition, Vol. 6, International Union of Biochemistry and Elsevier/North-Holland, 1981, pp. 203-205		
	PPP	GOUGH, et al., "Molecular Cloning of Seven Mouse Immunoglobulin κ Chain Messenger Ribonucleic Acids," <u>Biochemistry</u> , 19:2702-2710 (1980)		
	QQQ	GUARENTE, et al., "Improved Methods for Maximizing Expression of a Cloned Gene: a Bacterium That Synthesizes Rabbit β-Globin," <u>Cell</u> , 20:543-553 (1980)		
	RRR	HEATH and PLAYFAIR, "Cytokines as immunological adjuvants," <u>Vaccine</u> , 10(7):427-434 (1992)		
	SSS	HESS, et al., "The effect of granulocyte-macrophage-colony-stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients," <u>Journal of Viral Hepatitis</u> , 3:149-153 (1996)		
	TTT	HITZMAN, et al., "Secretion of Human Interferons by Yeast," <u>Science</u> , 219:620-625 (1983)		
	UUU	HOZUMI, et al., "Characterization of a mouse DNA clone containing an immunoglobulin variable region gene," <u>Nucleic Acids Research</u> , 5(6):1779-1799 (1978)		
	VVV	JAFFEE, et al., "Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor – Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation," <u>Journal of Clinical Oncology</u> , 19(1):145-156 (2001)		
	WW	KEMP and COWMAN, "Direct immunoassay for detecting <u>Escherichia coli</u> colonies that contain polypeptides encoded by cloned DNA segments," <u>Proc. Natl. Acad. Sci. USA</u> , 78(7):4520-4524 (1981)		
	XXX	KNUTH, et al., "Cellular and humoral immune responses against cancer: implications for cancer vaccines," <u>Current Opinion in Immunology</u> , 3:659-664 (1991)		
	YYY	KUROKAWA, et al., "Expression of human immunoglobulin E ε chain cDNA in <u>E. coli</u> ," <u>Nucleic Acids Research</u> , 11(10):3077-3085 (1983)		
	ZZZ	LAU and KAN, "Construction of Recombinant DNA Libraries Using Expression Cosmid Vectors That Can Shuttle Between Bacteria and Mammalian Cells," <u>Plasmids and Transforming Vectors</u> , Fed Proc. 1983, Abstract 2362, p. 2161		
JW	AAA	LESLIE, et al., "Humoral immune responses in mice using gamma inulin preparations as adjuvants for hepatitis B vaccines," <u>Immunol. Cell Biol.</u> , 68:107-112 (1990)		
Examiner <u>J. Roark</u>		Date Considered: 3/25/04		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.				

FORM PTO-1449 (modified)
 To: U.S. Department of Commerce
 (PW FORM PAT-1449)
 Patent and Trademark Office

Atty. Dkt. No.	M#	Client Ref.
027579	0302598	

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date: March 11, 2004

Page **6** of **9**

Applicant: Gold, et al.

Appln. No.: 09/927,121

Filing Date: August 10, 2001

Examiner: Jessica H. Roark | Group Art Unit: 1644

FOREIGN PATENT DOCUMENTS	English Abstract	Translation Readily Available
--------------------------	------------------	-------------------------------

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)				
JH ²	BBB	LEVY, "Cytokine Fusion Proteins with Enhanced Immunogenicity," NIH Grant No. 1R01AI037219-01 (1994)		
	CCC	LIESCHKE and BURGESS, "Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor," Part 1, <u>New England Journal of Medicine</u> , 327(1): 28-35 (1992)		
	DDD	LIESCHKE and BURGESS, "Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor," Part 2, <u>New England Journal of Medicine</u> , 327(2): 99-106 (1992)		
	EEE	LIESCHKE, et al., "Effects of Bacterially Synthesized Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Advanced Malignancy," <u>Annals of Internal Medicine</u> , 110:357-364 (1989)		
	FFFF	Summary in <u>Molecular Cloning, A Laboratory Manual</u> , Mantitis, et al., eds., Cold Spring Harbor Laboratory, New York (1982), p 433.		
	GGG	MARTIN, et al., "Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhGM-CSF) in the Treatment of Chronic Hepatitis B," <u>American Association for the Study of Liver Diseases Abstracts of Papers</u> , 16(2, Pt. 2):67A, Abstract 89 (1992)		
	HHH	MASUCCI, et al., "CM-CSF Augments the Cytotoxic Activity of Mononuclear Cells in ADCC Using MAb 17-1A. Both α -IFN and TNF- α Acts Synergistically," Sixth NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, March 7-10, 1989, Abstract 143		
	IIII.	MASUCCI, et al., "Chemotherapy and Immunotherapy of Colorectal Cancer," <u>Med. Oncol. & Tumor Pharmacother.</u> , 8(3):207-220 (1991)		
	JJJJ.	MASUCCI, et al., "Granulocyte-monocyte colony-stimulating factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A)," <u>Cancer Immunol. Immunother.</u> , 31:231-235 (1990)		
	KKK	McCUNE and MARQUIS, "Interleukin 1 as an Adjuvant for Active Specific Immunotherapy in a Murine Tumor Model," <u>Cancer Research</u> 50:1212-1215 (1990)		
	LLLL	MERCEREAU-PUIJALON, et al., "Expressions of Cloned Eukaryotic Genes in Microorganisms," in Pettersson et al., eds., <u>Expression of Eukaryotic Viral and Cellular Genes</u> , Academic Press, 1981, pp. 295-303		
	MMM	MEUER, et al., "Low-Dose Interleukin-2 Induces Systemic Immune Responses Against HBsAg in Immunodeficient Non-Responders to Hepatitis B Vaccination," <u>The Lancet</u> , January 7, 1989, pp. 15-18		
JH ²	NNN	MEUER, et al., "Monocyte Defect in Hemodialysis Patients Supports Nonresponsiveness to Hepatitis B Vaccination and Development of HBsAg Carrier State," in Zukerman, ed., <u>Viral Hepatitis and Liver Disease</u> , Alan R. Liss, Inc., New York, pp. 711-713 (1988)		

Examiner *J. Roark*

Date Considered: 3/25/04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified) To: U.S. Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office		Atty. Dkt. No.	M#	Client Ref.
		027579	0302598	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				
Date: March 11, 2004		Page 7 of 9	Applicant: Gold, et al.	
			Appln. No.: 09/927,121	
			Filing Date: August 10, 2001	
			Examiner: Jessica H. Roark Group Art Unit: 1644	
FOREIGN PATENT DOCUMENTS				English Abstract Translation Readily Available
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)				
JW	OOO	MEUER, et al., "Selective Blockade of the Antigen-Receptor-Mediated Pathway of T Cell Activation in Patients with Impaired Primary Immune Responses," <u>J. Clin. Invest.</u> 80:743-749 (1987)		
	PPP	MONK, et al., "Heavy-Chain Mutants Derived from Y _{2b} Mouse Myeloma: Characterization of Heavy-Chain Messenger Ribonucleic Acid, Proteins, and Secretion in Deletion Mutants and Messenger Ribonucleic Acid in Y _{2a} Mutant Progeny," <u>Biochemistry</u> , 20:2330-2339 (1981)		
	QQQ	MORRISON, "Transfer and Expression of Immunoglobulin Genes," <u>Ann. Rev. Immunol.</u> , 2:239-256, (1984)		
	RRR	MORRISSEY, et al., "Granulocyte-Macrophage Colony-Stimulating Factor Augments the Primary Antibody Response by Enhancing the Function of Antigen-Presenting Cells," <u>Journal of Immunology</u> , 139(4):1113-1119 (1987)		
	SSS	MORSTYN, et al., "Pharmacology of colony-stimulating factors," in Abbott, et al., eds., <u>Trends in Pharmacological Sciences</u> , 10:154-159 (1989)		
	TTT	MOXON, "The scope of immunisation," <u>The Lancet</u> , Feb. 24, 1990, pp. 448-451		
	UUU	MULLIGAN and BERG, "Expression of Bacterial Gene in Mammalian Cells," <u>Science</u> , 209:1422-1427 (1980)		
	VVV	MULLIGAN and BERG, "Selection for animal cells that express the <u>Escherichia coli</u> gene coding for xanthine-guanine phosphoribosyltransferase," <u>Proc. Natl. Acad. Sci USA</u> , 78(4):2072-2076 (1981)		
	WW	MYERS and GUSTAFSON, "Adjuvants for Human Vaccine Usage: A Rational Design," Chapter 32 in Cryz, ed., <u>Vaccines and Immunotherapy</u> , Pergamon Press, Inc., New York, 1991, pp. 404-410		
	XXX	NEUBERGER, "Expression and regulation of immunoglobulin heavy chain gene transfecting into lymphoid cells," <u>EMBO Journal</u> , 2(8):1373-1378 (1983)		
	YYY	NISONOFF and RIVERS, "Recombination of a Mixture of Univalent Antibody Fragments of Different Specificity," <u>Archives of Biochemistry and Biophysics</u> , Vol. 93, Academic Press, New York and London, pp. 460-462 (1961)		
	ZZZ	O'BRIEN et al., "Cloning and sequencing of the cDNA for ovine granulocyte-macrophage colony-stimulating factor (GM-CSF)," <u>Immunology and Cell Biology</u> 69:51-55 (1991)		
	AAA	OCHI et al., "Functional immunoglobulin M production after transfection of cloned immunoglobulin heavy and light chain genes into lymphoid cells," <u>Proc. Natl. Acad. Sci. USA</u> , 80:6351-6355 (1983)		
	BBB	OCHI et al., "Transfer of a cloned immunoglobulin light-chain gene to mutant hybridoma cells restores specific antibody production," <u>Nature</u> 302:340-342 (1983)		
M	CCC	OI et al., "Immunoglobulin gene expression in transformed lymphoid cells," <u>Proc. Natl. Acad. Sci. USA</u> , 80:825-829 (1983)		
<i>Examiner [Signature]</i>		Date Considered: <u>3/25/04</u>		
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.				

FORM PTO-1449 (modified) To: U.S. Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office	Atty. Dkt. No.	M#	Client Ref.
		027579	0302598
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant: Gold, et al.		
	Appln. No.: 09/927,121		
	Filing Date: August 10, 2001		
Date: March 11, 2004	Page 8 of 9	Examiner: Jessica H. Roark	Group Art Unit: 1644

FOREIGN PATENT DOCUMENTS		English Abstract	Translation Readily Available
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)			
JHR DDD	OKAYAMA and BERG, "A cDNA Cloning Vector That Permits Expression of cDNA Inserts in Mammalian Cells," <i>Molecular and Cellular Biology</i> 3(2):280-289 (1983)		
EEE	PARDOLL, "Gene-Targeted Immunotherapy of Renal Cancer," Grant No. 1U01CA061551-01 (Abstract), http://commons.cit.nih.gov/crisp3/CRISP_LIB , accessed 9/4/2002		
FFFF	PELLICER et al., "Altering Genotype and Phenotype by DNA-Medicated Gene Transfer," <i>Science</i> , 209:1414-1421 (1980)		
GGG	PICARD and SCHAFFNER, "Correct transcription of a cloned mouse immunoglobulin gene in vivo," <i>Proc. Natl. Acad. Sci. USA</i> , 80:417-421 (1983)		
HHH	QUIROGA et al., "Recombinant γ -Interferon as Adjuvant to Hepatitis B Vaccine in Hemodialysis Patients," <i>Hepatology</i> , 12(4):661-663 (1990)		
IIIII.	RASO and GRIFFIN, "Hybrid Antibodies with Dual Specificity for the Delivery of Ricin to Immunoglobulin-bearing Target Cells," <i>Cancer Research</i> , 41:2073-2078 (1981)		
JJJJ.	REEVES et al., "Construction and Transfer Into Mammalian Cells of a Vector Containing Insect Histone Genes," in Lurquin, et al., eds., <i>Genetic Engineering in Eukaryotes</i> , Plenum Press, New York, pp. 73-85 (1983)		
KKK	RICKE et al., "Expression of Immunoglobulin Genes Introduced into Mouse Lymphoid Cell Lines," <i>Journal of Cellular Biochemistry</i> , Suppl. 7A:133 (Abstract 0341) (1983)		
LLLL	RICE and BALTIMORE, "Regulated expression of an immunoglobulin κ gene introduced into a mouse lymphoid cell line," <i>Proc. Natl. Acad. Sci. USA</i> , 79:7862-7865 (1982)		
MMM	ROBERTS, "A <i>lac</i> Promoter System for the Overexpression of Prokaryotic and Eukaryotic Genes in <i>E. Coli</i> ," in Rodriguez, et al., eds., <i>Promoters, Structure and Function</i> , Praeger Publishers, New York, 1982, pp. 452-461		
NNN	ROBERTS, et al., "Synthesis of simian virus 40 t antigen in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 76(11):5596-5600 (1979)		
OOO	ROBERTS, et al., "A general method for maximizing the expression of a cloned gene," <i>Proc. Natl. Acad. Sci. USA</i> , 76(2):760-764 (1979)		
PPP	SAMBROOK, et al., "Cloning into Bacteriophage M13 Vectors and Transfection of Competent Bacteria," in <i>Molecular Cloning, A Laboratory Manual</i> , 2 nd ed., Cold Spring Harbor Laboratory Press, New York, 1989, pp. 4.33-4.34		
QQQ	SCHRADER, "Peptide Regulatory Factors and Optimization of Vaccines," <i>Molecular Immunology</i> , 28(3):295-299 (1991)		
RRR	SIMS, et al., "Somatic Mutation in Genes for the Variable Portion of the Immunoglobulin Heavy Chain," <i>Science</i> , 216:309-311 (1982)		
SJR SSS	SOUTHERN and BERG, "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter," <i>Journal of Molecular and Applied Genetics</i> , 1:327-341 (1982)		

Examiner <i>J. Roark</i>	Date Considered: <i>3/25/04</i>
EXAMINER Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 (modified)
 To: U.S. Department of Commerce
 (PW FORM PAT-1449)
 Patent and Trademark Office

Atty. Dkt. No.	M#	Client Ref.
027579	0302598	
Applicant: Gold, et al.		
Appln. No.: 09/927,121		
Filing Date: August 10, 2001		
Examiner: Jessica H. Roark Group Art Unit: 1644		

Date: March 11, 2004

Page **9** of **9**

FOREIGN PATENT DOCUMENTS		English Abstract	Translation Readily Available
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)			
DNL	TTT STAFFORD and QUEEN, "Cell-type specific expression of a transfected immunoglobulin gene," <u>Nature</u> , 306:77-79 (1983)		
	UUU STEWARD, et al., "Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions -- a phase I dose-toxicity study," <u>Br. J. Cancer</u> , 59:142-145 (1989)		
	VVV STEWARD, et al., "Clinical Studies with Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," <u>International Journal of Cell Cloning</u> , 8:335-346, Suppl. 1 (1990)		
	WW SUBRAMANI, "Expression of the Mouse Dihydrofolate Reductase Complementary Deoxyribonucleic Acid in Simian Virus 40 Vectors," <u>Molecular and Cell Biology</u> , 2:854-864 (1981)		
	XXX SULLIVAN and MANDELL, "The role of cytokines in infection," <u>Current Opinion in Infectious Diseases</u> , 4:344-349 (1991)		
	YYY TANIGUCHI, et al., "Expression of the human fibroblast interferon gene in <u>Escherichia coli</u> ," <u>Proc. Natl. Acad. Sci. USA</u> , 77(9):5230-5233 (1980)		
	ZZZ TONEGAWA, "Somatic Generation of Immune Diversity," Nobel lecture, December 8, 1987		
	AAA VALLE, et al., "Synthesis and secretion of mouse immunoglobulin chains from <u>Xenopus</u> oocytes," <u>Nature</u> , 291:338-340 (1981)		
	BBB VALLE, et al., "Anti-ovalbumin monoclonal antibodies interact with their antigen in internal membranes of <u>Xenopus</u> oocytes," <u>Nature</u> , 300:71-74 (1982)		
	CCC VOSE, et al., "Granulocyte-monocyte colony-stimulating factor (GM-CSF): Answers or More Questions?," <u>Annals of Internal Medicine</u> , 116(3):261-262 (1992)		
	DDD WETZEL, et al., "Expression in <u>Escherichia coli</u> of a chemically synthesized gene for a "mini-C" analog of human proinsulin," <u>Gene</u> , 16:63-71 (1981)		
	EEE WIGLER, et al., "Transformation of Mammalian Cells with Genes from Prokaryote and Eucaryotes," <u>Cell</u> , 16:777-785 (1979)		
Site	FFFF WILLIAMS, et al., "Cytoplasmic Inclusion Bodies in <u>Escherichia coli</u> Producing Biosynthetic Human Insulin Proteins," <u>Science</u> , 215:687-689 (1982)		
GGG			
HHH			
IIIIIII.			
JJJJ			

Examiner *J. Roark*

Date Considered: 3/29/04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)

Patent and Trademark Office



Atty.
Dkt. No.

M#

Client Ref.

027579

0302598

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date: December 16, 2003

Page 1 of 1

Applicant: Gold, et al.

Appln. No.: 09/927,121

Filing Date: August 10, 2001

Examiner: Jessica H. Roark Group Art Unit: 1644

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
JWZ	AR 5,679,356	10/21/1997	Bonnem			
	BR					
	CR					
	DR					
	ER					
	FR					
	GR					
	HR					
	IR					

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
JWZ	JR 0351876 A2	01/24/1990	EP	Kishimoto		
	KR					
	LR					

OTHER (Including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

JWZ	MR	ALTMANN, et al., "Insect Cells as Hosts for the Expression of Recombinant Glycoproteins," <i>Glycoconjugate Journal</i> , 16:109-123 (1999)				
JWZ	NR	SCHRADER, "Peptide Regulatory Factors and Optimization of Vaccines," <i>Molecular Immunology</i> , 28(3):295-299 (1991)				
JWZ	OR	WALSH, "Biopharmaceutical Benchmarks - 2003," <i>Nature Biotechnology</i> , 21(8):865-870 (2003)				
	PR					
	QR					
	RR					
	SR					
	TR					
	UR					
	VR					
	WR					
	XR					

Examiner *J. Roark*

Date Considered: 3/1/04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-003

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

APR 03 2002 06

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1 of 11

Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	032077.0003.UTL1

TECH CENTER 1600/2900
APR 19 2002

RECEIVED

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
JH2	AA	3,969,287		Boehringer Mannheim GmbH	7/13/1976	
	AB	4,195,128		Bayer Aktiengesellschaft	3/25/1980	
	AC	4,229,537		New York University	10/21/1980	
	AD	4,247,642		Sumitomo Chem. Co.	1/27/1981	
	AE	4,330,440		Development Finance Corp. of New Zealand	5/18/1982	
	AF	4,661,586		The Board of Trustees of the Leland Stanford Junior University	4/28/1987	
	AG	4,745,051		The Texas A&M University System	5/17/1988	
	AH	4,816,397		Celltech Limited	3/28/1989	
	AI	5,053,224		Koprowski et al.	10/1/1991	
	AJ	5,122,464		Celltech Limited; The University Court of the Univ. of Glasgow	6/16/1992	
	AK	5,227,159		Richard A. Miller	7/13/1993	
	AL	5,281,699		Tanox Biosystems, Inc.	1/25/1994	
	AM	5,612,035		The Immune Response Corporation	3/18/1997	
	AN	5,650,150		Stephen D. Gillies	7/22/1997	
	AO	5,789,206		Myriad Genetics, Inc.	8/4/1998	
	AP	5,792,445		Bracco International B.V.	8/11/1998	
	AQ	5,861,164		The Immune Response Corp.	1/19/1999	
DIP	AR	5,972,334		Genitope Corp.	10/26/1999	

Examiner Signature

Date Considered

3/25/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

APR 03 2002



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

11

Complete If Known


Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	032077.0003.UTL1

CENTER
1600
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
20100
20101
20102
20103
20104
20105
20106
20107
20108
20109
20110
20111
20112
20113
20114
20115
20116
20117
20118
20119
20120
20121
20122
20123
20124
20125
20126
20127
20128
20129
20130
20131
20132
20133
20134
20135
20136
20137
20138
20139
20140
20141
20142
20143
20144
20145
20146
20147
20148
20149
20150
20151
20152
20153
20154
20155
20156
20157
20158
20159
20160
20161
20162
20163
20164
20165
20166
20167
20168
20169
20170
20171
20172
20173
20174
20175
20176
20177
20178
20179
20180
20181
20182
20183
20184
20185
20186
20187
20188
20189
20190
20191
20192
20193
20194
20195
20196
20197
20198
20199
20200
20201
20202
20203
20204
20205
20206
20207
20208
20209
20210
20211
20212
20213
20214
20215
20216
20217
20218
20219
20220
20221
20222
20223
20224
20225
20226
20227
20228
20229
20230
20231
20232
20233
20234
20235
20236
20237
20238
20239
20240
20241
20242
20243
20244
20245
20246
20247
20248
20249
20250
20251
20252
20253
20254
20255
20256
20257
20258
20259
20260
20261
20262
20263
20264
20265
20266
20267
20268
20269
20270
20271
20272
20273
20274
20275
20276
20277
20278
20279
20280
20281
20282
20283
20284
20285
20286
20287
20288
20289
20290
20291
20292
20293
20294
20295
20296
20297
20298
20299
202000
202001
202002
202003
202004
202005
202006
202007
202008
202009
202010
202011
202012
202013
202014
202015
202016
202017
202018
202019
202020
202021
202022
202023
202024
202025
202026
202027
202028
202029
202030
202031
202032
202033
202034
202035
202036
202037
202038
202039
202040
202041
202042
202043
202044
202045
202046
202047
202048
202049
202050
202051
202052
202053
202054
202055
202056
202057
202058
202059
202060
202061
202062
202063
202064
202065
202066
202067
202068
202069
202070
202071
202072
202073
202074
202075
202076
202077
202078
202079
202080
202081
202082
202083
202084
202085
202086
202087
202088
202089
202090
202091
202092
202093
202094
202095
202096
202097
202098
202099
2020100
2020101
2020102
2020103
2020104
2020105
2020106
2020107
2020108
2020109
2020110
2020111
2020112
2020113
2020114
2020115
2020116
2020117
2020118
2020119
2020120
2020121
2020122
2020123
2020124
2020125
2020126
2020127
2020128
2020129
2020130
2020131
2020132
2020133
2020134
2020135
2020136
2020137
2020138
2020139
2020140
2020141
2020142
2020143
2020144
2020145
2020146
2020147
2020148
2020149
2020150
2020151
2020152
2020153
2020154
2020155
2020156
2020157
2020158
2020159
2020160
2020161
2020162
2020163
2020164
2020165
2020166
2020167
2020168
2020169
2020170
2020171
2020172
2020173
2020174
2020175
2020176
2020177
2020178
2020179
2020180
2020181
2020182
2020183
2020184
2020185
2020186
2020187
2020188
2020189
2020190
2020191
2020192
2020193
2020194
2020195
2020196
2020197
2020198
2020199
2020200
2020201
2020202
2020203
2020204
2020205
2020206
2020207
2020208
2020209
2020210
2020211
2020212
2020213
2020214
2020215
2020216
2020217
2020218
2020219
2020220
2020221
2020222
2020223
2020224
2020225
2020226
2020227
2020228
2020229
2020230
2020231
2020232
2020233
2020234
2020235
2020236
2020237
2020238
2020239
2020240
2020241
2020242
2020243
2020244
2020245
2020246
2020247
2020248
2020249
2020250
2020251
2020252
2020253
2020254
2020255
2020256
2020257
2020258
2020259
2020260
2020261
2020262
2020263
2020264
2020265
2020266
2020267
2020268
2020269
2020270
2020271
2020272
2020273
2020274
2020275
2020276
2020277
2020278
2020279
2020280
2020281
2020282
2020283
2020284
2020285
2020286
2020287
2020288
2020289
2020290
2020291
2020292
2020293
2020294
2020295
2020296
2020297
2020298
2020299
2020300
2020301
2020302
2020303
2020304
2020305
2020306
2020307
2020308
2020309
2020310
2020311
2020312
2020313
2020314
2020315
2020316
2020317
2020318
2020319
2020320
2020321
2020322
2020323
2020324
2020325
2020326
2020327
2020328
2020329
2020330
2020331
2020332
2020333
2020334
2020335
2020336
2020337
2020338
2020339
2020340
2020341
2020342
2020343
2020344
2020345
2020346
2020347
2020348
2020349
2020350
2020351
2020352
2020353
2020354
2020355
2020356
2020357
2020358
2020359
2020360
2020361
2020362
2020363
2020364
2020365
2020366
2020367
2020368
2020369
2020370
2020371
2020372
2020373
2020374
2020375
2020376
2020377
2020378
2020379
2020380
2020381
2020382
2020383
2020384
2020385
2020386
2020387
2020388
2020389
2020390
2020391
2020392
2020393
2020394
2020395
2020396
2020397
2020398
2020399
2020400
2020401
2020402
2020403
2020404
2020405
2020406
2020407
2020408
2020409
2020410
2020411
2020412
2020413
2020414
2020415
2020416
2020417
2020418
2020419
2020420
2020421
2020422
2020423
2020424
2020425
2020426
2020427
2020428
2020429
2020430
2020431
2020432
2020433
2020434
2020435
2020436
2020437
2020438
2020439
2020440
2020441
2020442
2020443
2020444
2020445
2020446
2020447
2020448
2020449
2020450
2020451
2020452
2020453
2020454
2020455
2020456
2020457
2020458
2020459
2020460
2020461
2020462
2020463
2020464
2020465
2020466
2020467
2020468
2020469
2020470
2020471
2020472
2020473
2020474
2020475
2020476
2020477
2020478
2020479
2020480
2020481
2020482
2020483
2020484
2020485
2020486
2020487
2020488
2020489
2020490
2020491
2020492
2020493
2020494
2020495
2020496
2020497
2020498
2020499
2020500
2020501
2020502
2020503
2020504
2020505
2020506
2020507
2020508
2020509
2020510
2020511
2020512
2020513
2020514
2020515
2020516
2020517
2020518
2020519
2020520
2020521
2020522
2020523
2020524
2020525
2020526
2020527
2020528
2020529
2020530
2020531
2020532
2020533
2020534
2020535
2020536
2020537
2020538
2020539
2020540
2020541
2020542
2020543
2020544
2020545
2020546
2020547
2020548
2020549
2020550
2020551
2020552
2020553
2020554
2020555
2020556
2020557
2020558
2020559
2020560
2020561
2020562
2020563
2020564
2020565
2020566
2020567
2020568
2020569
2020570
2020571
2020572
2020573
2020574
2020575
2020576
2020577
2020578
2020579
2020580
2020581
2020582
2020583
2020584
2020585
2020586
2020587
2020588
2020589
2020590
2020591
2020592
2020593
2020594
2020595
2020596
2020597
2020598
2020599
2020600
2020601
2020602
2020603
2020604
2020605
2020606
2020607
2020608
2020609
2020610
2020611
2020612
2020613
2020614
2020615
2020616
2020617
2020618
2020619
2020620
2020621
2020622
2020623
2020624
2020625
2020626
2020627
2020628
2020629
2020630
2020631
2020632
2020633
2020634
2020635
2020636
2020637
2020638
2020639
2020640
2020641
2020642
2020643
2020644
2020645
2020646
2020647
2020648
2020649
2020650
2020651
2020652
2020653
2020654
2020655
2020656
2020657
2020658
2020659
2020660
2020661
2020662
2020663
2020664
2020665
2020666
2020667
2020668
2020669
2020670
2020671
2020672
2020673
2020674
2020675
2020676
2020677
2020678
2020679
2020680
2020681
2020682
2020683
2020684
2020685
2020686
2020687
2020688
2020689
2020690
2020691
2020692
2020693
2020694
2020695
2020696
2020697
2020698
2020699
2020700
2020701
2020702
2020703
2020704
2020705
2020706
2020707
2020708
2020709
2020710
2020711
2020712
2020713
2020714
2020715
2020716
2020717
2020718
2020719
2020720
2020721
2020722
2020723
2020724
2020725
2020726
2020727
2020728
2020729
2020730
2020731
2020732
2020733
2020734
2020735
2020736
2020737
2020738
2020739
2020740
2020741
2020742
2020743
2020744
2020745
2020746
2020747
2020748
2020749
2020750
2020751
2020752
2020753
2020754
2020755
2020756
2020757
2020758
2020759
2020760
2020761
2020762
2020763
2020764
2020765
2020766
2020767
2020768
2020769
2020770
2020771
2020772
2020773
2020774
2020775
2020776
2020777
2020778
2020779
2020780
2020781
2020782
2020783
2020784
2020785
2020786
2020787
2020788
2020789
2020790
2020791
2020792
2020793
2020794
2020795
2020796
2020797
2020798
2020799
2020800
2020801
2020802
2020803
2020804
2020805
2020806
2020807
2020808
2020809
2020810
2020811
2020812
2020813
2020814
2020815
2020816
2020817
2020818
2020819
2020820
2020821
2020822
2020823
2020824
2020825
2020826
2020827
2020828
2020829
2020830
2020831
2020832
2020833
2020834
2020835
2020836
2020837
2020838
2020839
2020840
2020841
2020842
2020843
2020844
2020845
2020846
2020847
2020848
2020849
2020850
2020851
2020852
2020853
2020854
2020855
2020856
2020857
2020858
2020859
2020860
2020861
2020862
2020863
2020864
2020865
2020866
2020867
2020868
2020869
2020870
2020871
2020872
2020873
2020874
2020875
2020876
2020877
2020878
2020879
2020880
2020881
2020882
2020883
2020884
2020885
2020886
2020887
2020888
2020889
2020890
2020891
2020892
2020893
2020894
2020895
2020896
2020897
2020898
2020899
2020900
2020901
2020902
2020903
2020904
2020905
2020906
2020907
2020908
2020909
2020910
2020911
2020912
2020913
2020914
2020915
2020916
2020917
2020918
2020919
2020920
2020921
2020922
2020923
2020924
2020925
2020926
2020927
2020928
2020929
2020930
2020931
2020932
2020933
2020934
202

Please type a plus sign (+) inside this box → +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

11

Complete if Known

Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA

Attorney Docket Number 032077.0003.UTL1

RECEIVED
APR 03 2002

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JHR	BF	ARDEN, et al., "Human T-Cell Receptor Variable Gene Segment Families," <u>Immunogenetics</u> , 42:455-500 (1995)	
JHR	BG	BENDANDI, et al., "Complete Molecular Remissions Induced by Patient-specific Vaccination Plus Granulocyte-monocyte Colony-stimulating Factor Against Lymphoma," <u>Nature Medicine</u> , 5:1171-1177 (1999)	
JHR	BH	BERINSTEIN, et al., "Idiotypic Variation in a Human B Lymphoma Cell Line," <u>The Journal of Immunology</u> , Vol. 144, No. 2: 752-758 (1990)	
JHR	BI	BROWN, et al., "Antiidiotype Antibody Therapy of B-Cell Lymphoma," <u>Seminars in Oncology</u> , 16:199-210 (1989)	
JHR	BJ	BROWN, et al., "The Prognostic Significance of Immunophenotype in High-grade Non-Hodgkin's Lymphoma," <u>Histopathology</u> , Vol. 14: 621-627 (1989)	
JHR	BK	BROWN, et al., "Treatment of B-Cell Lymphomas with Anti-idiotype Antibodies Alone and in Combination with Alpha Interferon," <u>Blood</u> , 73(3):651:661 (1989)	
JHR	BL	CAMPBELL, et al., "Idiotype Vaccination Against Murine B Cell Lymphoma, Humoral and Cellular Requirements for the Full Expression of Antitumor Immunity," <u>The Journal of Immunology</u> , 145:1029-1036 (1990)	
JHR	BM	CAMPBELL, et al., "Immunotherapy of Established Murine B Cell Lymphoma, Combination of Idiotype Immunization and Cyclophosphamide," <u>The Journal of Immunology</u> , 141:3227-3233 (1988)	
JHR	BN	CARAYANNOPOULOS, et al., "Recombinant Human IgA Expressed in Insect Cells," <u>Proc. Natl. Acad. Sci.</u> , Vol. 91: 8348-8352 (1994)	
JHR	BO	CASARES, et al., "Antigen-specific Downregulation of T Cells by Doxorubicin Delivered through a Recombinant MHC II-peptide Chimera," <u>Nature Biotechnology</u> , 19:142-147 (2001)	
JHR	BP	CASPAR, et al., "Idiotype Vaccines for Non-Hodgkin's Lymphoma Induce Polyclonal Immune Responses That Cover Mutated Tumor Idiotypes: Comparison of Different Vaccine Formations," <u>Blood</u> , Vol. 90, No. 9, pp. 3699-3706 (November 11, 1997)	

Examiner Signature

Date Considered

3/25/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

APR 03 2002 JC58

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of

11

Complete if Known

Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	032077.0003.UTL1

TECH CENTER 1600/2900
APR 09 2002

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JHL	BQ	CATON, et al., "Influenza Virus Hemagglutinin-specific Antibodies Isolated from a Combinatorial Expression Library are closely related to the Immune Response of the Donor," <u>Proc. Natl. Acad. Sci.</u> , Vol. 88: 6450-6454 (1990)	
JHL	BR	CHEN and LEVY, "Induction of Autoantibody Responses to GM-CSF by Hyperimmunization with an Id-GM-CSF Fusion Protein," <u>The Journal of Immunology</u> , 154, pp. 3105-3117 (1995)	
JHL	BS	CHEN, et al., "Idiotype-Cytokine Fusion Proteins as Cancer Vaccines, Relative Efficacy of IL-2, IL-4, and Granulocyte-Macrophage Colony-Stimulating Factor," <u>The Journal of Immunology</u> , 153:4775-4787 (1994)	
JHL	BT	CHESON, et al., "Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas," <u>J. Clin. Oncol.</u> , 17(4):1244 (1999)	
JHL	BU	CHUNDURU, "Exploitation of the Vβ8.2 T Cell Receptor in Protection against Experimental Autoimmune Encephalomyelitis Using a Live Vaccinia Virus Vector," <u>J. Immunol.</u> , 156:4940-45, (1996)	
JHL	BV	CHUNG, et al., "Functional three-domain single-chain T-cell receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 91:12654-12658 (1994)	
JHL	BW	CLARK, et al., "Comparison of Human and Mouse T-Cell Receptor Variable Gene Segment Subfamilies," <u>Immunogenetics</u> , 42:531-540 (1995)	
JHL	BX	CLEARLY, et al., "Clustering of Extensive Somatic Mutations in the Variable Region of an Immunoglobulin Heavy Chain Gene from a Human B Cell Lymphoma," <u>Cell Press</u> , Vol. 44: 97-106 (1986)	
JHL	BY	DALEY, et al., "Idiotype-Specific Transplantation Resistance to MOPC-315: Abrogation by Post-Immunization Thymectomy," <u>The Journal of Immunology</u> , vol. 120, No. 5 (1978)	
JHL	BZ	DOENECKE, et al., "Rapid Amplification of cDNA ends (RACE) Improves the PCR-based Isolation of Immunoglobulin Variable Region Genes from Murine and Human Lymphoma Cells and Cell Lines," <u>BTS Leukemia</u> , 11:1787-1792 (1997)	
JHL	CA	DRANOFF, et al., "Vaccination with Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-Macrophage Colony-Stimulating Factor Stimulates Potent, Specific, and Long-Lasting Anti-Tumor Immunity," <u>Proc. Natl. Acad. Sci. USA</u> , 90(8):3539-3543 (1993)	
JHL	CB	EILAT, et al., "Secretion of a soluble, chimeric γδ T-cell receptor – immunoglobulin heterodimer," <u>Proc. Natl. Acad. Sci. USA</u> , 89:6871-6875 (1992)	

Examiner Signature

J. H. Lee

Date Considered

3/29/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

O I P E
APR 08 2002
P A T E N T & T R A D E M A R K S O C I E T Y
U.S. Patent and Trademark Office

PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5 of 11

Complete if Known

Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA

Attorney Docket Number 032077.0003.UTL1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JML	CC •	ENGEL, et al., "High-Efficiency Expression and Solubilization of Functional T Cell Antigen Receptor Heterodimers," <u>Science</u> , 256:1318-1321 (1992)	
JML	CD •	GEORGE, et al., "Idiotypic Vaccination as a Treatment for a B Cell Lymphoma," <u>The Journal of Immunology</u> , Vol. 141: 2168-2174 (1988)	
JML	CE •	GILLIES, et al., "Biological Activity and in Vivo Clearance of Antitumor Antibody/Cytokine Fusion Proteins," <u>Bioconjugate Chem.</u> , 4:230-235 (1993)	
JML	CF •	GOLD, Daniel P., "TCR V Gene Usage in Autoimmunity," <u>Current Opinion in Immunology</u> , 6:907-912 (1994)	
JML	CG •	GOLD, et al., "T-Cell Receptor Peptides as Immunotherapy for Autoimmune Disease," <u>Critical Reviews Immunol.</u> , 17:507-10 (1997)	
JML	CH •	GRABSTEIN, et al., "Induction of Macrophage Tumocidal Activity by Granulocyte-Macrophage Colony-Stimulating Factor," <u>Science</u> , Vol. 232:506-508 (1986)	
JML	CI •	GREENBERG, Philip D., "Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells," <u>Advances in Immunology</u> , 49:281-355 (1991)	
JML	CJ •	GREGOIRE, et al., "Engineered secreted T-cell receptor αβ heterodimers," <u>Proc. Natl. Acad. Sci USA</u> , Vol. 88, pp. 8077-8081 (September 1991)	
JML	CK •	HASEMANN, et al., "High-level Production of a Functional Immunoglobulin Heterodimer in a Baculovirus Expression System," <u>Proc. Natl. Acad. Sci.</u> , 87:3942-3946 (1990)	
JML	CL •	HASEMANN, et al., "Mutational Analysis of Arsonate Binding by a CRI _{A+} Antibody, V _H and V _L Junctional Diversity are Essential for Binding Activity," <u>The Journal of Biological Chemistry</u> , 266:7626-7632 (1991)	
JML	CM •	HASEMANN, et al., "Mutational Analysis of the Cross-Reactive Idiotype of the A Strain Mouse," <u>The Journal of Immunology</u> , 147:3170-3179 (1991)	
JML	CN •	HEUFLER, et al., "Granulocyte/Macrophage Colony-Stimulating Factor and Interleukin 1 Mediate the Maturation of Murine Epidermal Langerhans Cells into Potent Immunostimulatory Dendritic Cells," <u>J. Exp. Med.</u> , 167(2):700-05 (1988)	

Examiner Signature

Date Considered

3/29/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

APR 08 2002

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

6

of

11

Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	032077.0003.UTL1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JW	CO *	HINUMA, et al., "A Novel Strategy for Converting Recombinant Viral Protein into High Immunogenic Antigen," <u>Federation of European Biochemical Societies</u> , 288:138-142 (1991)	
JW	CP *	HSU, et al., "Tumor-Specific Idiotype Vaccines in the Treatment of Patients with B-Cell Lymphoma – Long-Term Results of a Clinical Trial," <u>Blood</u> , Vol. 89, No. 9, pp. 3129-35 (May 1, 1997)	
JW	CQ *	HSU, et al., "Vaccination of Patients with B-cell Lymphoma Using Autologous Antigen-pulsed Dendritic Cells," <u>Nature Medicine</u> , 2:52-58 (1996)	
JW	CR *	HUSE, et al., "General of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <u>Science</u> , 246(4935):1275-1281 (1989)	
JW	CS *	JIANG, et al., "Murine CD8+ Cells that Specifically Delete Autologous CD4+ T Cells Expressing Vb8 TCR: A Role of the Qa-1 Molecule," <u>Immunity</u> , 2:185-94 (1995)	
JW	CT *	KAPPLER, et al., "Binding of a soluble αβ T-cell receptor to superantigen/major histocompatibility complex ligands," <u>Proc. Natl. Acad. Sci. USA</u> , 91:8462-8466 (1994)	
JW	CU *	KUMAR, et al., "Recombinant T Cell Receptor Molecules Can Prevent and Reverse Experimental Autoimmune Encephalomyelitis," <u>J. Immunol.</u> , 159:5150-5156 (1997)	
JW	CV *	KURUCZ, et al., "A bacterially expressed single-chain Fv construct from the 2B4 T-cell receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 90:3830-3834 (1993)	
JW	CW *	KWAK, et al., "Combined Syngenic Bone Marrow Transplantation and Immunotherapy of a Murine B-Cell Lymphoma: Active Immunization with Tumor-Derived Idiotypic Immunoglobulin," <u>Blood</u> , 76(11):2411-2417 (1990)	
JW	CX *	KWAK, et al., "Idiotypic Vaccination as Therapy for Multiple Myeloma," <u>Seminars in Hematology</u> , 36:34-37 (1999)	
JW	CY *	KWAK, et al., "Introduction of Immune Responses in Patients with B-Cell Lymphoma Against the Surface-Immunoglobulin Idiotype Expressed by Their Tumors," <u>N. Eng. J. Med.</u> , 327:1209-1215 (1992)	
JW	CZ *	KWAK, et al., "Transfer of Myeloma Idiotype-specific Immunity from an Actively Immunised Marrow Donor," <u>The Lancet</u> , 345:1016-1020 (1995)	

Examiner Signature

Date Considered

3/24/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

APR 08 2002

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

7

of

11

Complete if Known

Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA

Attorney Docket Number 032077.0003.UTL1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Citation No. ²	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Type ³
JKL	DA	KWAK, et al., "Vaccination with Syngeneic, Lymphoma-derived Immunoglobulin Idiotype Combined with Granulocyte/Macrophage colony-stimulating Factor Primes Mice for a Protective T-cell Response," <u>Proc. Natl. Acad. Sci.</u> , 93:10972-10977 (1996)	
JLR	DB	LEBOWITZ, et al., "Soluble, High-Affinity Dimers of T-Cell Receptors and Class II Major Histocompatibility Complexes: Biochemical Probes for Analysis and Modulation of Immune Responses," <u>Cell. Immunol.</u> , 192:175-184 (1999)	
JLR	DC	LEVITISKY, et al., "Immunization with Granulocyte-Macrophage Colony-Stimulating Factor-Trasduced, but Not B7-1-Transduced, Lymphoma Cells Primes Idiotype-Specific T Cells and Generates Potent Systemic Antitumor Immunity," <u>J. Immunol.</u> , 156 (10):3858-3865 (1996)	
JLR	DD	LEVY, et al., "Mutational Hot Spots in Ig V Region Genes of Human Follicular Lymphomas," <u>J. Exp. Med.</u> , 168(2):475-489 (1988)	
JLR	DE	LIN, et al., "Expression of T Cell Antigen Receptor Heterodimers in a Lipid-Linked Form," <u>Science</u> , 249:677-679 (1990)	
JLR	DF	MAECKER and LEVY, "Spontaneous T Cell Antigen Receptor Variants of a Human T Leukemia Cell Line," <u>J. Immunol.</u> , 141:2994-3002, (1985)	
JLR	DG	MALKOVSKA, et al., "Human T Cells in hu-PBL-SCID Mice Proliferate in Response to Daudi Lymphoma and Confer anti-tumour Immunity," <u>Clin. Exp. Immunol.</u> , 96:158-165 (1994)	
JLR	DH	MALONEY, et al., "Monoclonal Anti-Idiotype Antibody Therapy of B-Cell Lymphoma: The Addition of a Short Course of Chemotherapy Does Not Interfere With the Antitumor Effect Nor Prevent the Emergence of Idiotype-Negative Variant Cells," <u>Blood</u> , 80(6):1502-1510 (1992)	
JLR	DI	MASSAIA, et al., "Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy," <u>Blood</u> , 94:673-683 (1999)	
JLR	DJ	MCKEEVER, et al., "Immunization with Soluble BDC 2.5 T Cell Receptor-Immunoglobulin Chimeric Protein: Antibody Specificity and Protection of Nonobese Diabetic Mice against Adoptive Transfer of Diabetes by Maternal Immunization," <u>J. Exp. Med.</u> , 184:1755-1768 (1996)	
JLR	DK	MEEKER, et al., "A Clinical Trial of Anti-Idiotype Therapy for B Cell Malignancy," <u>Blood</u> , 65:1349-1363 (1985)	

Examiner Signature


Date Considered

3/25/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

8

of

11

Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA

Attorney Docket Number 032077.0003.UTL1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JN2	DL •	MEEKER, et al., "Emergence of Idiotype Variants During Treatment of B-Cell Lymphoma with Anti-Idiotype Antibodies," <u>N. Eng. J. Med.</u> , 312:1658-1665 (1985)	
JN2	DM •	MILLER, et al., "Treatment of B-Cell Lymphoma with Monoclonal Anti-idiotype Antibody," <u>N. Eng. J. Med.</u> , 306(9):517-522 (1982)	
JN2	DN •	MINTY, et al., "Molecular Cloning of the MCP-3 Chemokine Gene and Regulation of its Expression," <u>Eur. Cytokine Netw.</u> , 4(2):99-110 (1993)	
JN2	DO •	MORRISSEY, et al., "Granulocyte-Macrophage Colony-Stimulating Factor Augments the Primary Antibody Response by Enhancing the Function of Antigen-Presenting Cells," <u>J. Immunol.</u> , 139(4):1113-1119 (1987)	
JN2	DP •	MROCKOWSKI, et al., "Secretion of Thermostable DNA Polymerase Using a Novel Baculovirus Vector," <u>J. Biol Chem.</u> , 269:13522-13528 (1994)	
JN2	DQ •	MULLINAX, et al., "Identification of Human Antibody Fragment Clones Specific for Tetanus Toxoid in a Bacteriophage A Immunoexpression Library," <u>Proc. Natl. Acad. Sci. USA</u> , 87(20):8095-8099 (1990)	
JN2	DR •	NELSON, et al., "Tumor-Specific, Cytotoxic T-Lymphocyte Response After Idiotype Vaccination for B-Cell, Non-Hodgkin's Lymphoma," <u>Blood</u> , 88:580-589 (1996)	
JN2	DS •	NESBIT, et al., "Production of a Functional Monoclonal Antibody Recognizing Human Colorectal Carcinoma Cells from a Baculovirus Expression System," <u>Immunol. Methods</u> , 151:201-208 (1992)	
JN2	DT •	NOVOTNY, et al., "A soluble, single-chain T-cell receptor fragment endowed with antigen-combining properties," <u>Proc. Natl. Acad. Sci. USA</u> , 88:8646-8650 (1991)	
JN2	DU •	O'HERRIN, et al., "Analysis of the Expression of Peptide - Major Histocompatibility Complexes Using High Affinity Soluble Divalent T Cell Receptors," <u>J. Exp. Med.</u> , 186(8):1333-1345 (1997)	
JN2	DV •	ODENDAHL, et al., "Disturbed Peripheral B Lymphocyte Homeostasis in Systemic Lupus Erythematosus," <u>J. Immunol.</u> , 165(10):5970-5979 (2000)	
JN2	DW •	OFFNER, et al., "Vaccination with BV8S2 Protein Amplifies TCR-Specific Regulation and Protection Against Experimental Autoimmune Encephalomyelitis in TCR BV8S2 Transgenic Mice," <u>J. Immunol.</u> , 161:2178-2186 (1998)	

Examiner Signature

Date Considered

3/24/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

APR 08 2002

PTO/SB/08A (08-00)

Please type a plus sign (+) inside this box →

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete If Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

9

of

11

Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA

Attorney Docket Number 032077.0003.UTL1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JHL	DX	OGAWA, et al., "Increase in CD95 (Fas/APO-1)-positive CD4+ and CD8+ Cells in Peripheral Blood Derived from Patients with Autoimmune Hepatitis or Chronic Hepatitis C with Autoimmune Phenomena," <u>J. Gastroenterol. Hepatol.</u> , (1):69-75 (2000)	
JIR	DY	OKADA, et al., "TCR Vaccines for Active Immunotherapy of T Cell Malignancies," <u>J. Immunol.</u> , 159:5516-5527 (1997)	
JIR	DZ	OPDENAKKER, et al., "Human Monocyte Chemotactic Protein-3 (MCP-3): Molecular Cloning of the cDNA and Comparison with other Chemokines," <u>Biochem. Biophys. Res. Comm.</u> , 191(2):535-542 (1993)	
JIR	EA	ORLANDI, et al., "Cloning Immunoglobulin Variable Domains for Expression by the Polymerase Chain Reaction," <u>Proc. Natl. Acad. Sci. USA</u> , 86(10) 3833-3837 (1989)	
JIR	EB	POTTER, et al., "Anti-idiotypic Antibody D12 and Superantigen SPA Both Interact with Human V _H 3-encoded Antibodies on the External Face of the Heavy Chain Involving FR1, CDR2, and FR3," <u>Molecular Immunology</u> , 35:1179-1187 (1998)	
JIR	EC	POTTER, et al., "Staphylococcal Protein A Binding to V _H 3 Encoded Immunoglobulins," <u>Intern. Rev. Immunol.</u> , 14:291-308 (1997)	
JIR	ED	POTTER, et al., "Staphylococcal Protein A Simultaneously Interacts with Framework Region 1, Complementarity-Determining Region 2, and Framework Region 3 on Human V _H 3-Encoding Ig's," <u>The Journal of Immunology</u> , 157:2982-2988 (1996)	
JIR	EE	POTTER, et al., "The Cross-Reactive Idiotypes Recognized by the Monoclonal Antibodies 9G4 and LC1 are Located in Framework Region 1 of Two Non-Overlapping Subsets of Human V _H 4 Family Encoded Antibodies," <u>Scand. J. Immunol.</u> , 40:43-49 (1994)	
JIR	EF	PROOST, et al., "Human Monocyte Chemotactic Proteins-2 and -3: Structural and Functional Comparison with MCP-1," <u>J. Leukoc. Biol.</u> , 59(1):67-74 (1996)	
JIR	EG	RAUER and KAISER, "Demonstration of Anti-HuD Specific Oligoclonal Bands in the Cerebrospinal Fluid from Patients with Paraneoplastic Neurological Syndromes Qualitative Evidence of Anti-HuD Specific IgG-synthesis in the Central Nervous System," <u>J. Neuroimmunol.</u> , 111(1-2):241-244 (2000)	
JIR	EH	ROWEN, et al., "The Complete 685-Kilobase DNA Sequence of the Human β T Cell Receptor Locus," <u>Science</u> , 272:1755-1762 (1996)	
JIR	EI	RUBERTI, et al., "The Use of the RACE Method to Close Hybridoma cDNA when V Region Primers Fail," <u>Journal of Immunological Methods</u> , 173:33-39 (1994)	
JIR	EJ	SAKATO, et al., "Suppression of MOPC-167 Growth <i>In Vivo</i> by Immunization Against the Idiotype of the MOPC-167 Myeloma Protein," <u>Microbiol. Immunol.</u> , 23:927-931 (1979)	

Examiner Signature

Date Considered

3/29/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

APR 08 2002

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

10

of

11

Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	032077.0003.UTL1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JIR	EK	SANTOLI, et al., "Amplification of IL-2-Driven T Cell Proliferation by Recombinant Human IL-3 and Granulocyte-Macrophage Colony-Stimulating Factor," <i>J. Immunol.</i> , 141(20):519-526 (1988)	
JIR	EL	SINCLAIR, et al., "PCR Strategies for Isolation of the 5' End of an Immunoglobulin-encoding Bovine cDNA," <i>Gene</i> , 167:285-289 (1995)	
JIR	EM	SINGH and O'HAGAN, "Advances in Vaccine Adjuvants," <i>Nature Biotech</i> , 17:1075-1081 (1999)	
JIR	EN	SMITH, et al., "Direct Evidence for an Intracellular Role for IFN-γ" Microinjection of Human IFN-γ Induces Ia Expression on Murine Macrophages, <i>J. Immunol.</i> , 144(5):1777-1782 (1990)	
JIR	EO	STEVENSON and GORDON, "Immunization with Idiotypic Immunoglobulin Protects Against Development of B Lymphocytic Leukemia, But Emerging Tumor Cells can Evade Antibody Attack by Modulation," <i>J. Immunol.</i> , 130(2):970-973 (1983)	
JIR	EP	TAO and LEVY, "Idiotype/granulocyte-macrophage Colony-stimulating Factor Fusion Protein as a Vaccine for B-Cell Lymphoma," <i>Nature</i> , 362(6422):755-758 (1993)	
JIR	EQ	TESSIER, et al., "Enhanced Secretion from Insect Cells of a Foreign Protein Fused to the Honeybee Melittin Signal Peptide," <i>Gene</i> , 98:177-183 (1991)	
JIR	ER	VAN HALL, et al., "Identification of a Novel Tumor-Specific CTL Epitope Presented by RMA, EL-4, and MBL-2 Lymphomas Reveals Their Common Origin," <i>J. Immunol.</i> , 165:869-877 (2000)	
JIR	ES	VAINIENE, et al., "Natural Immunodominant and Experimental Autoimmune Encephalomyelitis-Protective Determinants Within the Lewis Rat Vβ8.2 Sequence Include CDR2 and Framework 3 Idiotypes," <i>Journal of Neuroscience Research</i> , 43:137-145 (1996)	
JIR	ET	VANDENBARK, et al., "Human TCR as Antigen: Homologies and Potentially Cross-Reactive HLA-DR2-Restricted Epitopes Within the AV and BV CDR2 Loops," <i>Critical Reviews Immunol.</i> , 20:57-83 (2000)	
JIR	EU	WAISMAN, et al., "Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity," <i>Nature Med.</i> , 2(8):899-905 (1996)	
JIR	EV	WARE, et al., "Human CD8+ Lymphocyte Clones Specific for T Cell Receptor VB Families Expressed on Autologous CD4+ T Cells," <i>Immunity</i> , 2:177-184 (1995)	
JIR	EW	WARREN and CATZ, "Kinetic Profiles of Cerebrospinal Fluid Anti-MBP in Response to Intravenous MBP Synthetic Peptide DENP ₈₅ VVHFFKNIVTP ₉₆ RT in Multiple Sclerosis Patients," <i>Mult. Scler.</i> , 6(5):300-311 (2000)	

Examiner Signature

Date Considered

3/29/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST-3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

APR 08 2002

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

11

of

11

Complete if Known

Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	032077.0003.UTL1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ZHL	EX	WEBER, et al., "Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor," <u>Nature</u> , 356:793-796 (1992)	
ZHL	EY	WILSON, et al., "Results of a phase I clinical trial of T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations," <u>J. Neuroimmunol.</u> , 76:15-28 (1997)	
ZHL	EZ	YOUNG, et al., "Comparison of the Effects of IL-3, Granulocyte-Macrophage Colony-Stimulating Factor, and Macrophage Colony-Stimulating Factor in Supporting Monocyte Differentiation in Culture," <u>J. Immunol.</u> , 145(2):607-615 (1990)	
ZHL	FA	ZHANG, et al., "Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosys," <u>J. Immunol.</u> , 166(1):6-10 (2001)	
ZHL	FB	ZHANG, et al., "Increased Frequency of Interleukin 2-responsive T Cells Specific for Myelin Basic Protein and Proteolipid Protein in Peripheral Blood and Cerebrospinal Fluid of Patients with Multiple Sclerosis," <u>J. Exp. Med.</u> , 179:973-984 (1994)	

Examiner
Signature Date
Considered 3/25/07

'EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.